Abstract:Abstract Chemotherapy-resistance is the major obstacle for endometrial carcinoma patient administration. Accumulated evidences indicate that metformin sensitizes cancers from several different sites to chemotherapy drugs and reverses progestin resistance in endometrial cancer. Our group has demonstrated that metformin reverses progestin resistance and enhances the rate of cell-killing induced by chemotherapeutic agents in endometrial cancer cells by downregulating GloI expression. Recent study has revealed that aberrant expression of IDH1 contribute to chemotherapy resistance. However, the role of IDH1 in metformin induced chemotherapy sensitivity is not well characterized. As a critical enzyme of the tricarboxylic acid (TCA) cycle, IDH1 catalyzes isocitrate to produce α-ketoglutarate (α-KG), a substrate of TET1, which control TET1-mediated epigenetic modulation of the target genes, including the chemotherapy-resistant genes. In the present study, we have found that IDH1 is overexpressed in endometrial cancers compared with benign endometrial lesions and normal endometria by immunohistochemical analysis of specimens (200 cases of endometrial cancers, 10 cases of benign endometrial lesions and 10 cases of normal endometria). Tissue microarray immunohistochemical detection showed the expression of IDH1, TET1 and 5hmc was positively correlated in different pathological types of endometrial tissue. Interestingly, we found that metformin reduces expression of IDH1 at protein levels with a time- and dose-manners in endometrial cancer cells. Furthermore, overexpression of IDH1 increased TET1 at protein level and blocked metformin-sensitized endometrial cancer to chemotherapy drugs, whereas decrease IDH1 expression lessened TET1 expression and paralleled with the attenuated chemotherapy-resistance. Mechanistic investigations revealed that TET1 involved in metformin-enhanced chemotherapy sensitivity via IDH1 by western blotting and DNA dot blotting assays, this may attribute to that reduced production of α-KG resulted from metformin-suppressing IDH1 is not enough to start TET1-mediated epigenetic modulation of chemotherapy resistant genes. Overall, our findings demonstrate that IDH1 regulates α-KG level and TET1 expression, which in turn affecting metformin mediated endometrial cancer chemotherapeutic sensitivity. Our study suggests IDH1 is a potential target to overcome cisplatin and paclitaxel resistance in endometrial cancer. Citation Format: Mingzhu Bai, Zhenbo Zhang, Yinhua Yu, Youji Feng. Metformin sensitizes endometrial cancer cells to chemotherapy by inhibiting IDH1-TET1 pathway. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 248.

Mefformin Sensitizes Endometrial Cancer Cells To Chemotherapy By Inhibiting Idh1-Tet1 Pathway

Abstract 248: Metformin Sensitizes Endometrial Cancer Cells to Chemotherapy by Inhibiting IDH1-TET1 Pathway

Metformin Sensitizes Endometrial Cancer Cells to Chemotherapy Through IDH1-induced Nrf2 Expression Via an Epigenetic Mechanism

Metformin Sensitizes Endometrial Cancer Cells to Progestin by Targeting TET1 to Downregulate Glyoxalase I Expression

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents.

Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1

Metformin Reverses Progestin Resistance In Endometrial Cancer Cells By Downregulating Gloi Expression

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Metformin Inhibits Estrogen‐dependent Endometrial Cancer Cell Growth by Activating the AMPK–FOXO1 Signal Pathway

Metformin Synergistically Suppress Tumor Growth with Doxorubicin and Reverse Drug Resistance by Inhibiting the Expression and Function of P-glycoprotein in MCF7/ADR Cells and Xenograft Models

Abstract 2856: Inhibition of Glycolysis Sensitizes Cancer Cells to Metformin-Induced Anoikis

Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS in Vitro and in Vivo.

Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions

Metformin Revert Insulin‐induced Oxaliplatin Resistance by Activating Mitochondrial Apoptosis Pathway in Human Colon Cancer HCT116 Cells

Metformin Sensitizes Hypoxia-Induced Gefitinib Treatment Resistance of HNSCC Via Cell Cycle Regulation and EMT Reversal

Inhibitory Effects Of Metformin On Epithelial-Mesenchymal Transition Of Cd44+/Cd117+Ovarian Cancer Stem Cells

Abstract 4734: Inhibitory Effects of Metformin on Epithelial-Mesenchymal Transition of CD44+/CD117+ Ovarian Cancer Stem Cells

Abstract 6636: Metformin suppresses tumor immune evasion through downregulation of PD-L1 expression in cancer cells and PD-1 expression in NK cells and T cells